Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead Sciences

Revenues up 11% in the quarter with antiviral combos

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 
 
1Q Revenues: $2.5 billion (+11%)
 
1Q Earnings: $722.2 million (+64%)
 
Comments: Antiviral product sales increased 7% to $2.1 billion driven by Complera/Eviplera ($148.2 million, +184%) and Stribild ($92.1 million), partially offset by an 8% decrease in Truvada sales to $702.0 million. Cardiovascular product sales increased 26% to $214.4 million, driven primarily by strong Letairis sales ($118.1 million, +35%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters